Aspirin and serum estrogens in postmenopausal women
It has been known for some time that a small daily dose of aspirin reduces the risk of someone getting breast cancer. An added bonus, is low dose aspirin also reduces the risk of colon cancer. This study is another one confirming this fact, as well as ahowing that the aspirin intake has no effect on menopausal women’s oestrogen level.
Aspirin and serum estrogens in postmenopausal women: A randomized controlled clinical trial
Cancer Prevention Research, 06/16/2014 Clinical Article
Duggan C, et al. – This study suggest a reduced risk of breast cancer among women who use aspirin. Result suggest that a single daily administration of 325 mg of aspirin for 6 months had no effect on serum estrogens or SHBG in postmenopausal women. Larger doses or longer duration of aspirin administration may be needed to affect circulating estrogens.
- In a randomized placebo–controlled trial, the authors evaluated the effects of 6–months administration of 325 mg/day aspirin on serum estrogens (estradiol, estrone, free estradiol, bioavailable estradiol) and sex hormone binding globulin [SHBG] in 144 healthy postmenopausal women.
- Eligible participants, recruited 2005 – 2007, were not taking nonsteroidal anti–inflammatory medication including aspirin > 2 times/week or menopausal hormone therapy, and had a BI–RAD mammographic density classification of 2, 3, or 4.
- The intervention effects (intent–to–treat) were evaluated by differences in the geometric mean outcome changes at 6 months between aspirin and placebo groups using generalized estimating equations (GEE).
- Participants were a mean 59.4 (SD 5.4) years, with mean body mass index (BMI) of 26.4 (SD) 5.4 kg/m2.
- Between baseline and 6–months, none of the serum estrogens or SHBG changed substantially and there were no differences between groups.
- Stratifying by BMI did not change results